| Identification | Back Directory | [Name]
Urabrelimab | [CAS]
2249722-58-3 | [Synonyms]
Urabrelimab
Urabrelimab (anti-CD47)
Research Grade Urabrelimab
Research Grade Urabrelimab(DHG17602) |
| Hazard Information | Back Directory | [Uses]
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction[1]. | [in vivo]
Urabrelimab (SRF231) administration leads to profound tumor growth inhibition in models of multiple myeloma, diffuse large B cell lymphoma and Burkitt's lymphoma as a single agent and in combination with opsonizing antibodies. In the Raji xenograft model, single agent therapy leads to 112% tumor growth inhibition[1]. | [References]
[1] Holland P M, et al. CD47 monoclonal antibody SRF231 is a potent inducer of macrophage-mediated tumor cell phagocytosis and reduces tumor burden in murine models of hematologic malignancies. 2016. |
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|